It has high antibacterial activity against most aerobic Gram-negative bacteria, including Escherichia coli, Klebsiella pneumoniae and Oxytobacter, aerogenes, Cloacae, Proteus, Serratia, Citrobacter, Shigella and other Enterobacteriaceae, as well as influenza bacilli, gonococci, meningococci, etc. It also has good antibacterial effect against Pseudomonas aeruginosa, but has poor antibacterial effect against some Pseudomonas and Acinetobacter species other than Pseudomonas aeruginosa, and has no antibacterial activity against aerobic Gram-positive bacteria such as Staphylococcus and Streptococcus, as well as anaerobic bacteria. Aztreonam exerts its effect by binding to penicillin-binding protein 3 (PBP3) on the cell membrane of sensitive aerobic Gram-negative bacteria.

Irbesartan is a potent, orally active, selective angiotensin-II receptor (AT1 subtype) antagonist. It should block all AT1 receptor-mediated effects of angiotensin-II, regardless of the source or synthetic pathway of angiotensin-II. Its selective antagonism of angiotensin-II receptors (AT1) results in increased plasma renin and angiotensin-II levels and decreased plasma aldosterone levels. Serum potassium is not significantly affected when the recommended dose of irbesartan is administered alone to patients without electrolyte disturbances. Irbesartan does not inhibit angiotensin-converting enzyme (ACE kininase II), which generates angiotensin-II, and can also degrade bradykinin into inactive metabolites. The activity of irbesartan does not require metabolic activation.

This product is a broad-spectrum β-lactam antibiotic with a strong ability to inhibit bacterial cell wall synthesis and can kill most Gram-positive and Gram-negative bacteria.

It is a specific enzyme inhibitor that blocks the metabolism of imipenem in the kidney and increases the concentration of imipenem parent drug in the urinary tract.